| Literature DB >> 27386154 |
Didier F Pisani1, Olivier Dumortier2, Guillaume E Beranger1, Virginie Casamento2, Rayane A Ghandour1, Maude Giroud1, Nadine Gautier2, Thierry Balaguer3, Jean-Claude Chambard1, Kirsi A Virtanen4, Pirjo Nuutila5, Tarja Niemi6, Markku Taittonen7, Emmanuel Van Obberghen8, Charlotte Hinault8, Ez-Zoubir Amri1.
Abstract
Human brown adipocytes are able to burn fat and glucose and are now considered as a potential strategy to treat obesity, type 2 diabetes and metabolic disorders. Besides their thermogenic function, brown adipocytes are able to secrete adipokines. One of these is visfatin, a nicotinamide phosphoribosyltransferase involved in nicotinamide dinucleotide synthesis, which is known to participate in the synthesis of insulin by pancreatic β cells. In a therapeutic context, it is of interest to establish whether a potential correlation exists between brown adipocyte activation and/or brite adipocyte recruitment, and adipokine expression. We analyzed visfatin expression, as a pre-requisite to its secretion, in rodent and human biopsies and cell models of brown/brite adipocytes. We found that visfatin was preferentially expressed in mature adipocytes and that this expression was higher in brown adipose tissue of rodents compared to other fat depots. However, using various rodent models we were unable to find any correlation between visfatin expression and brown or brite adipocyte activation or recruitment. Interestingly, the situation is different in humans where visfatin expression was found to be equivalent between white and brown or brite adipocytes in vivo and in vitro. In conclusion, visfatin can be considered only as a rodent brown adipocyte biomarker, independently of tissue activation.Entities:
Keywords: PBEF; UCP1; hMADS; nampt; obesity; type 2 diabetes
Year: 2015 PMID: 27386154 PMCID: PMC4916889 DOI: 10.1080/21623945.2015.1122854
Source DB: PubMed Journal: Adipocyte ISSN: 2162-3945 Impact factor: 4.534